MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--TYRX, Inc. announced today that it has successfully implanted its AIGISRx device in 10,000 patients in the United States. The AIGISRx device is an antibacterial mesh technology that securely holds a pacemaker (PM) or implantable cardioverter defibrillator (ICD) in place to create a stable environment, while delivering antimicrobial agents, rifampin and minocycline. These antimicrobial agents have been shown to reduce infections associated with medical devices in multiple randomized controlled trials.
“The number of patients with serious CIED-related infections in the US continues to increase out of proportion to the increase in implantation rates. And with major infection rates of 3% to 4% being commonly seen, there is a need for a locally-delivered therapy to help prevent these infections. I began to utilize the antibacterial envelope in 2009 and have found it to be very effective for CIED infection prophylaxis,” remarked Peter Taylor, MD., MBA, FACC, Attending Physician, Orlando Health, Orlando Florida.
“Reaching this 10,000th AIGISRx implant milestone is a remarkable achievement and a testament to our team who has worked tirelessly and enthusiastically to develop this important technology to address a significant clinical need,” said Robert White, TYRX President and CEO. “Approximately one out of 50 patients in the U.S. experiences a major infection problem at a cost of approximately $50,000 per patient. The AIGISRx Antibacterial Envelope provides hospitals and clinicians with a way to improve patient outcomes while reducing the corresponding economic burden.”
About TYRX, Inc.
TYRX, Inc. commercializes innovative, implantable combination drug/device products focused on infection control including the AIGISRx® Antibacterial Envelope and the recently released AIGISRx® FS. AIGISRx® products contain antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac rhythm device (CRDM) related endocarditis, including “superbugs” or MRSA*.
Following commercial release in 2008, the AIGISRx Envelope has been implanted in over 10,000 patients nationwide. The company estimates that approximately 2% of all U.S. CRMD patients in 2010 will receive an AIGISRx product during their procedure.
TYRX, Inc. is an ISO 13485:2003 certified medical device manufacturer and its products utilize technology licensed exclusively from Rutgers, Baylor College of Medicine, and The University of Texas M. D. Anderson Cancer Center.
* Based upon preclinical in vitro and in vivo data. Data on file at TYRX and published in PACE 2009; 32(7) 898-907.
For more information, please visit www.TYRX.com.
Contact:
TYRX, Inc. Robert White, 732-246-8676 President and Chief Executive Officer bwhite@tyrx.com
